Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Ipilimumab or Relatlimab in Stage III-IV Melanoma
NCT02519322Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2016
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab and relatlimab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02519322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519322.